Reported 2 months ago
Pfizer has seen a turnaround this year, with a 9% increase in stock value and a consistent commitment to its dividend program, offering over a 5.3% yield. The company reported positive Q2 results, including a rise in revenues for the first time since late 2022 and expectations of significant cost savings. With a strong pipeline and promising growth prospects, Pfizer looks set to continue as a reliable dividend stock despite some risks ahead.
Source: YAHOO